sugar and semaglutide Semaglutides Wegovy Ozempic improve blood and reduce weight long-term Compounded Semaglutide for Women |

If Congress or CMS chooses not to extend the program past 2027, patient access could lapse, potentially reversing the health improvements achieved during the program

Researchers have also reported cardiovascular benefits, with several studies showing reductions in heart attack and stroke risk among individuals using GLP-1 therapies

Experimentation within your chosen injection day helps identify your personal comfort pattern

No long-term commitment required

Injectable Wegovy produced an average weight loss of around 15 percent in major trials, while tirzepatide, sold as Zepbound for obesity, has produced around 20 percent or more weight loss depending on dose and population